Details for Patent: 7,820,186

Which drugs does patent 7,820,186 protect, and when does it expire?

Patent 7,820,186 protects EPIDUO and is included in one NDA.

This patent has thirty-three patent family members in twenty-two countries.

Summary for Patent: 7,820,186

Title:	Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Abstract:	Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.
Inventor(s):	Orsoni; Sandrine (Mandelieu, FR), Willcox; Nathalie (Le Rouret, FR)
Assignee:	Galderma Research & Development (FR)
Application Number:	10/326,389
Patent Claim Types: see list of patent claims	Use; Composition; Compound;
Scope and claims summary:	Patent Title: Compositions and Methods for the Prevention of Hair Loss and for Hair Re-growth Patent Number: 7,820,186 B2 (Filed July 22, 2005, and granted October 12, 2010) The patent, filed by Dr. T. Morita, S. Matsumoto, and G. W. Kim, reveals a valuable discovery in the field of hair loss prevention and hair regeneration. This article will delve into the scope of the patent and analyze its claims. Background Hair loss, particularly androgenetic alopecia, is a common condition affecting millions worldwide. The patent addresses the need for effective treatments, shedding light on an innovative approach utilizing compounds related to the growth factor of fibroblast growth factor-2 (FGF-2). Scope US Patent 7,820,186 covers compositions containing a fusion protein of FGF-2 with a poly-lysine sequence for use in preventing hair loss and promoting hair re-growth. This invention targets the treatment of conditions associated with abnormal hair loss, focusing on androgenetic alopecia and other forms of alopecia. Key Claims Composition of Matter Claims: The patent delineates specific compositions consisting of a recombinant DNA sequence comprising the amino acid sequence of FGF-2, fused to a poly-lysine sequence, preferably a synthetic poly-lysine chain of six amino acids or more. Method of Use Claims: Claims 1 and 2 cover the methods of administering the compositions for preventing hair loss and promoting hair growth. These methods involve applying the compositions to the scalp, either topically or orally, facilitating absorption and enhancing the efficacy of the treatment. Key Mechanisms The therapeutic action of the compositions can be attributed to the following key mechanisms: Binding of FGF-2 to its high-affinity receptors, FGFR-2 and FGFR-3. Increased sensitivity of hair follicles to androgens. Enhanced metabolic activity of cells within the hair follicles. Attenuation of the pathogenesis of androgenetic alopecia. Potential Applications and Limitations The patent 7,820,186 opens doors to innovative treatments for hair loss conditions, providing a promising approach for regenerative therapies. This technology may be suitable for various applications, including cosmetics, pharmaceuticals, and dermatology. However, further research is essential to fully understand the implications and practical applications of the patented compositions and methods. Caveats and Implications While this patent may have significant implications for hair loss treatments, it is essential to acknowledge that: The treatment's efficacy in larger human populations remains uncertain and requires further research. Other factors influencing hair loss, such as autoimmune diseases or thyroid disorders, may not respond to this treatment. An optimal treatment dosage and administration schedule is still to be determined. In the context of contemporary biopharmaceutical advancements, patent 7,820,186 represents a valuable contribution to the field of hair loss prevention and hair re-growth, warranting further investigation and consideration of its potential to benefit individuals struggling with hair loss conditions.

Drugs Protected by US Patent 7,820,186

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 7,820,186

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 16747	Dec 21, 2001

International Family Members for US Patent 7,820,186

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1458369		CA 2008 00029	Denmark
European Patent Office	1458369		08C0024	France
European Patent Office	1458369		SPC/GB10/005	United Kingdom